AU2017327383B2 - Method of reducing thyroid-associated side effects - Google Patents

Method of reducing thyroid-associated side effects Download PDF

Info

Publication number
AU2017327383B2
AU2017327383B2 AU2017327383A AU2017327383A AU2017327383B2 AU 2017327383 B2 AU2017327383 B2 AU 2017327383B2 AU 2017327383 A AU2017327383 A AU 2017327383A AU 2017327383 A AU2017327383 A AU 2017327383A AU 2017327383 B2 AU2017327383 B2 AU 2017327383B2
Authority
AU
Australia
Prior art keywords
optionally substituted
group
alkyl
days
followed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017327383A
Other languages
English (en)
Other versions
AU2017327383A1 (en
Inventor
Mark Erion
Bruce Ito
Brian Lian
Hiroko Masamune
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabasis Therapeutics Inc
Viking Therapeutics Inc
Original Assignee
Metabasis Therapeutics Inc
Viking Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc, Viking Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of AU2017327383A1 publication Critical patent/AU2017327383A1/en
Application granted granted Critical
Publication of AU2017327383B2 publication Critical patent/AU2017327383B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
AU2017327383A 2016-09-16 2017-09-13 Method of reducing thyroid-associated side effects Active AU2017327383B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662396015P 2016-09-16 2016-09-16
US201662396025P 2016-09-16 2016-09-16
US62/396,025 2016-09-16
US62/396,015 2016-09-16
PCT/US2017/051410 WO2018053036A1 (en) 2016-09-16 2017-09-13 Method of reducing thyroid-associated side effects

Publications (2)

Publication Number Publication Date
AU2017327383A1 AU2017327383A1 (en) 2019-04-11
AU2017327383B2 true AU2017327383B2 (en) 2023-06-29

Family

ID=61619247

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017327383A Active AU2017327383B2 (en) 2016-09-16 2017-09-13 Method of reducing thyroid-associated side effects

Country Status (9)

Country Link
US (1) US20190255080A1 (enExample)
EP (1) EP3512523A4 (enExample)
JP (2) JP2019531346A (enExample)
KR (2) KR20240074912A (enExample)
CN (2) CN121695155A (enExample)
AU (1) AU2017327383B2 (enExample)
CA (1) CA3037146A1 (enExample)
MX (2) MX2019003032A (enExample)
WO (1) WO2018053036A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008542301A (ja) 2005-05-26 2008-11-27 メタバシス・セラピューティクス・インコーポレイテッド 脂肪性肝疾患の処置のための甲状腺ホルモン様薬剤
EP3541395A4 (en) 2016-11-21 2020-07-01 Viking Therapeutics, Inc. GLYCOGENOSIS TREATMENT METHODS
EP3634426A4 (en) 2017-06-05 2021-04-07 Viking Therapeutics, Inc. COMPOSITIONS FOR TREATMENT OF FIBROSE
CA3094167A1 (en) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
BR112021021923A2 (pt) * 2019-05-08 2022-02-22 Novartis Ag Anticorpos anti-cd40 para uso no tratamento de dm1 e insulite
RU2728261C2 (ru) * 2019-05-22 2020-07-28 Ирина Алексеевна Курникова Способ дифференциальной диагностики йоддефицитного и йодиндуцированного нарушения функции щитовидной железы у лиц, проживающих в регионах с йодным дефицитом
CN112457346B (zh) * 2019-08-19 2022-09-06 和博医药有限公司 一种并环THRβ受体激动剂化合物及其制备方法和用途
US12378268B2 (en) 2019-08-19 2025-08-05 Hepagene Therapeutics (HK) Limited Heterocyclic THR-β receptor agonist compound and preparation method and use therefor
JP7670687B2 (ja) * 2020-02-24 2025-04-30 へパジーン セラピューティクス （エイチケイ） リミテッド 複素環式ＴＨＲ－β受容体アゴニスト化合物ならびにその調製方法および使用
US11752161B2 (en) 2020-03-27 2023-09-12 Gannex Pharma Co., Ltd. Pharmaceutical compositions, method of making and method of using thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
WO2017184811A1 (en) * 2016-04-22 2017-10-26 Metabasis Therapeutics, Inc. Thyroid hormone receptor agonist and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
MXPA04012497A (es) * 2002-07-04 2005-07-14 Zealand Pharma As Glp-1 y metodos para tratar la diabetes.
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
JP2008542301A (ja) * 2005-05-26 2008-11-27 メタバシス・セラピューティクス・インコーポレイテッド 脂肪性肝疾患の処置のための甲状腺ホルモン様薬剤
WO2009089093A1 (en) * 2008-01-04 2009-07-16 Quatrx Pharmaceuticals Company Thyroid hormone receptor agonists
CA2732686C (en) * 2008-12-22 2017-10-03 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
WO2017184811A1 (en) * 2016-04-22 2017-10-26 Metabasis Therapeutics, Inc. Thyroid hormone receptor agonist and use thereof

Also Published As

Publication number Publication date
JP2019531346A (ja) 2019-10-31
EP3512523A4 (en) 2020-05-06
US20190255080A1 (en) 2019-08-22
NZ751857A (en) 2024-05-31
MX2023000887A (es) 2023-02-22
MX2019003032A (es) 2019-09-13
CA3037146A1 (en) 2018-03-22
JP2022174261A (ja) 2022-11-22
KR20240074912A (ko) 2024-05-28
BR112019005039A2 (pt) 2019-06-25
AU2017327383A1 (en) 2019-04-11
CN109922812A (zh) 2019-06-21
EP3512523A1 (en) 2019-07-24
CN121695155A (zh) 2026-03-20
JP7656574B2 (ja) 2025-04-03
WO2018053036A1 (en) 2018-03-22
KR20190060786A (ko) 2019-06-03

Similar Documents

Publication Publication Date Title
AU2017327383B2 (en) Method of reducing thyroid-associated side effects
JP2025016462A (ja) 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
AU2018280118B2 (en) Compositions for the treatment of fibrosis
EA030651B1 (ru) Замещенные ароматические соединения и связанный с ними способ лечения фиброза
CA3044059A1 (en) Method of treating glycogen storage disease
US20100222376A1 (en) Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders
JP5680412B2 (ja) レオヌリンの使用およびその組成物
JPH06279397A (ja) アミノ酸系末梢神経障害改善剤
BR112019005039B1 (pt) Método de redução dos efeitos colaterais associados à tireoide
RU2850978C1 (ru) Применение агониста рецептора сфингозин-1-фосфата
KR20070102694A (ko) 혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물
JP2024512510A (ja) 置換芳香族化合物及びその医薬組成物
EA042390B1 (ru) Способ терапевтического лечения фиброза
EA044268B1 (ru) Способ лечения неалкогольной жировой болезни печени

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)